Melinda Caballes

Melinda Caballes is an experienced Rare Disease Specialist currently at Amicus Therapeutics since May 2018, focusing on the launch of precision medicine therapies for rare diseases, including a new two-component therapy for Pompe Disease set to debut in Fall 2023. Prior roles include serving as a Biosimilars Portfolio Representative at Pfizer, where Melinda successfully navigated sales strategies for a new class of biologics, and as a Rare Disease Specialist at United Therapeutics Corporation, achieving rapid sales growth in a multi-state territory. Earlier positions at Actelion and Sanofi-Aventis involved specialty roles in orphan diseases and complex biologics, respectively, contributing to Melinda's expertise in developing awareness and executing product launches across various therapeutic areas. Melinda holds a BA in Communications and Marketing from the University of Louisville.